Foreword

The Substance Abuse and Mental Health Services Administration (SAMSA) is the US Department of Health and Human Services agency that leads public health efforts to advance the behavioral health of the nation. SAMHSA’s mission is to reduce the impact of substance abuse and mental illness on America’s communities.

The Treatment Improvement Protocol (TIP) series fulfills SAMHSA’s mission by providing science-based best-practice guidance to the behavioral health field. TIPs reflect careful consideration of all relevant clinical and health service research, demonstrated experience, and implementation requirements. Select nonfederal clinical researchers, service providers, program administrators, and patient advocates comprising each TIP’s consensus panel discuss these factors, offering input on the TIP’s specific topic in their areas of expertise to reach consensus on best practices. Field reviewers then assess draft content.

The talent, dedication, and hard work that TIP panelists and reviewers bring to this highly participatory process have helped bridge the gap between the promise of research and the needs of practicing clinicians and administrators to serve, in the most scientifically sound and effective ways, people in need of behavioral health services. We are grateful to all who have joined with us to contribute to advances in the behavioral health field.

Elinore F. McCance-Katz, MD, PhD

Assistant Secretary for Mental Health and Substance Use

SAMHSA

A. Kathryn Power, MEd

Acting Director

Center for Substance Abuse Treatment

SAMHSA

Frances M. Harding

Director

Center for Substance Abuse Prevention

SAMHSA

Paolo del Vecchio, MSW

Director

Center for Mental Health Services

SAMHSA

Daryl W. Kade, MA

Director

Center for Behavioral Health Statistics and Quality

SAMHSA

Executive Summary

The goal of treatment for opioid addiction or opioid use disorder (OUD) is remission of the disorder leading to lasting recovery. Recovery is a process of change through which individuals improve their health and wellness, live self-directed lives, and strive to reach their full potential. ¹⁸ This Treatment Improvement Protocol (TIP) reviews the use of the three US Food and Drug Administration (FDA)–approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD.

Introduction

Our nation faces a crisis of overdose deaths from opioids, including heroin, illicit fentanyl, and prescription opioids. These deaths represent a mere fraction of the total number of Americans harmed by opioid misuse and addiction. Many Americans now suffer daily from a chronic medical illness called “opioid addiction” or OUD (see the Glossary in Part 5 of this TIP for definitions). Healthcare professionals, treatment providers, and policymakers have a responsibility to expand access to evidence-based, effective care for people with OUD.

Estimated cost of the OPIOID EPIDEMIC was $504 BILLION in 2015. ⁵

An expert panel developed the TIP’s content based on a review of the literature and on their extensive experience in the field of addiction treatment. Other professionals also generously contributed their time and commitment to this project.

An estimated 1.8M AMERICANS have OUD related to opioid painkillers; 626K have heroin-related OUD. ³

The TIP is divided into parts so that readers can easily find the material they need. Part 1 is a general introduction to providing medications for OUD and issues related to providing that treatment. Some readers may prefer to go directly to those parts most relevant to their areas of interest, but everyone is encouraged to read Part 1 to establish a shared understanding of key facts and issues covered in detail in this TIP.

Following is a summary of the TIP’s overall main points and brief summaries of each of the five TIP parts.

Overall Key Messages

• 
  

  Addiction is a chronic, treatable illness. Opioid addiction, which generally corresponds with moderate to severe forms of OUD, often requires continuing care for effective treatment rather than an episodic, acute-care treatment approach.

OPIOID OVERDOSE caused 42,249 DEATHS nationwide in 2016—this exceeded the number caused by motor vehicle crashes. ^4,15

• 
  

  General principles of good care for chronic diseases can guide OUD treatment. Approaching OUD as a chronic illness can help providers deliver care that helps patients stabilize, achieve remission of symptoms, and establish and maintain recovery.

  
  
• 
  

  Patient-centered care empowers patients with information that helps them make better treatment decisions with the healthcare professionals involved in their care. Patients should receive information from their healthcare team that will help them understand OUD and the options for treating it, including treatment with FDA-approved medication.

  
  
• 
  

  Patients with OUD should have access to mental health services as needed, medical care, and addiction counseling, as well as recovery support services, to supplement treatment with medication.

  
  
• 
  

  The words you use to describe OUD and an individual with OUD are powerful. The TIP defines, uses, and encourages providers to adopt terminology that will not reinforce prejudice, negative attitudes, or discrimination.

  
  
• 
  

  There is no “one size fts all” approach to OUD treatment. Many people with OUD benefit from treatment with medication for varying lengths of time, including lifelong treatment. Ongoing outpatient medication treatment for OUD is linked to better retention and outcomes than treatment without medication. Even so, some people stop using opioids on their own; others recover through support groups or specialty treatment with or without medication.

  
  
• 
  

  The science demonstrating the effectiveness of medication for OUD is strong. For example, methadone, extended-release injectable naltrexone (XR-NTX), and buprenorphine were each found to be more effective in reducing illicit opioid use than no medication in randomized clinical trials, which are the gold standard for demonstrating efficacy in clinical medicine. ^9,11-13 Methadone and buprenorphine treatment have also been associated with reduced risk of overdose death. ^1,6,8,16,21

  
  
• 
  

  This does not mean that remission and recovery occur only through medication. Some people achieve remission without OUD medication, just as some people can manage type 2 diabetes with exercise and diet alone. But just as it is inadvisable to deny people with diabetes the medication they need to help manage their illness, it is also not sound medical practice to deny people with OUD access to FDA-approved medications for their illness.

  
  
• 
  

  Medication for OUD should be successfully integrated with outpatient and residential treatment. Some patients may benefit from different levels of care at different points in their lives, such as outpatient counseling, intensive outpatient treatment, inpatient treatment, or long-term therapeutic communities. Patients treated in these settings should have access to OUD medications.

2.1 MILLION people in the United States ages 12 and older have OUD involving PRESCRIPTION OPIOIDS, HEROIN, or both in 2016. ³

• 
  

  Patients treated with medications for OUD can benefit from individualized psychosocial supports. These can be offered by patients’ healthcare providers in the form of medication management and supportive counseling and/or by other providers offering adjunctive addiction counseling, recovery coaching, mental health services, and other services that may be needed by particular patients.

  
  
• 
  

  Expanding access to OUD medications is an important public health strategy. ⁸ The gap between the number of people needing opioid addiction treatment and the capacity to treat them with OUD medication is substantial. In 2012, the gap was estimated at nearly 1 million people, with about 80% of opioid treatment programs (OTPs) nationally operating at 80% capacity or greater. ¹⁰

  
  
• 
  

  Improving access to treatment with OUD medications is crucial to closing the wide gap between treatment need and treatment availability, given the strong evidence of effectiveness for such treatments. ¹⁰

  
  
• 
  

  Data indicate that medications for OUD are cost-effective and cost-beneficial. ^2,14